Research Papers

25 of 52 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Belgian Recommendations for Analytical Verification and Validation of Immunohistochemical Tests in Laboratories of Anat…
Verbeke H; Van Hecke D; Bauraing C; Dierick AM; Colleye O; Dalle I; Dewachter K; Guiot Y; Lequeu R; Vanderheyden N; Zwaenepoel K; Croes R.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
2/6 Transparent
Depigmentation of Melanin-containing Tissues Using Hypochlorous Acid to Enhance Hematoxylin-eosin and Immunohistochemic…
Wang L; Wang G.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
2/6 Transparent
Clinicopathologic Features and Immune Cell Subtypes Analysis of Tumor-infiltrating Lymphocytes Rich Invasive Breast Car…
Zhao Y; Huang T; Jin X; Gong XM; Lu YZ.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Effect of Surface Decalcification With Hydrochloric Acid on the Determination of Estrogen Receptor, Progesterone Recept…
Ping W; Xin R; Li Z; Yupeng C; Fangling S; Caihong R; Shun H; Sheng Z.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Polycystin-2 Associates With Malignancy in Meningiomas.
Assimakopoulou M; Christopoulou ME; Karamani V; Aletras AJ; Gatzounis G.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Study of the Utility of Myeloid Cell Nuclear Differentiation Antigen (MNDA) in the Diagnosis of Marginal Zone Lymphoma.
Gupta N; Roychoudry S; Sticco KL; Hsu P; Zhang X; Sheikh-Fayyaz S.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
2/6 Transparent
High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer.
Weidemann S; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Clauditz TS; Jacobsen F; Jansen K; Schmalfeldt B; Wölber L; Paluchowski P; Berkes E; Heilenkötter U; Sauter G; Uhlig R; Wilczak W; Steurer S; Simon R; Krech T; Marx A; Burandt E; Lebok P.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
2/6 Transparent
Reinventing Nuclear Histo-score Utilizing Inherent Morphologic Cutoffs: Blue-brown Color H-score (BBC-HS).
Price P; Ganugapati U; Gatalica Z; Kakadekar A; Macpherson J; Quenneville L; Rees H; Slodkowska E; Suresh J; Yu D; Lim HJ; Torlakovic EE.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2023
2/6 Transparent
Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.
Huang Q; Yu T; Li L; Zhang Q; Zhang S; Li B; Li X; Xiao W; Liu G.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Lessons Learned, Challenges Taken, and Actions Made for "Precision" Immunohistochemistry. Analysis and Perspectives Fro…
Nielsen S; Bzorek M; Vyberg M; Røge R.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
2/6 Transparent
Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC).
Dobritoiu F; Baltan A; Chefani A; Billingham K; Chenard MP; Vaziri R; Lacroix-Triki M; Waydelich A; Erb G; Andersson E; Cañamero M; Toro P; Wedden S; D'Arrigo C.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breas…
Komforti M; Downs-Kelly E; Sapunar F; Wijayawardana SR; Gruver AM; Badve SS.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Digital Image Analysis and Quantitative Bead Standards in Root Cause Analysis of Immunohistochemical Staining Variabili…
Rojansky R; Sompuram SR; Gomulia E; Natkunam Y; Troxell ML; Fernandez-Pol S.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
2/6 Transparent
Comparative Study of Modified Silver Nitrate Staining for the Detection of Helicobacter pylori.
Chu X; Xu J; Niu L.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Mutational Alterations of DNA Methylation-related Genes CTCF, ZFP57, and ATF7IP Genes in Colon Cancers.
Moon SW; Mo HY; Choi EJ; Yoo NJ; Lee SH.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Kalpakoff M; Hund S; Musser J; Roach C; Apostolaki A; Vilardo M; Peltz L; Watts B; LaPlaca C; Tabuena-Frolli S; DiMaio MA; Welcher R; Kulangara K.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association.
Lara H; Li Z; Abels E; Aeffner F; Bui MM; ElGabry EA; Kozlowski C; Montalto MC; Parwani AV; Zarella MD; Bowman D; Rimm D; Pantanowitz L.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2021
1/6 Transparent
UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones.
Parry S; Dowsett M; Dodson A.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2021
2/6 Transparent
Data
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2021
1/6 Transparent
Tissue Thickness Interferes With the Estimation of the Immunohistochemical Intensity: Introduction of a Control System …
Masuda S; Suzuki R; Kitano Y; Nishimaki H; Kobayashi H; Nakanishi Y; Yokoi H.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2021
1/6 Transparent
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.
Boyle TA; Khalil FK; Mino-Kenudson M; Sica GL; Moreira AL; Sholl LM; Knight MZ; Zhang L; Saller J; Varella-Garcia M; Berry LD; Chen H; Ellison KE; Rivard CJ; Kugler K; Wistuba II; Fujimoto J; Kwiatkowski DJ; Bunn PA; Kris MG; Haura EB; Hirsch FR; Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcin…
Miller RM; Nworu C; McKee L; Balcerzak D; Pham L; Pugh J; Liu YZ; Gustafson H; Marwah E; Lamb T; Clements J.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET.
Miller R; Thorne-Nuzzo T; Loftin I; McElhinny A; Towne P; Clements J.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z.
Appl Immunohistochem Mol Morphol (Unknown)
Published: 2019
2/6 Transparent
Funding Declared